Research on the Risk Warning Model and Prevention Strategies for Acute Kidney Injury Associated With Cyclosporine Based on Explainable Deep Neural Networks and Therapeutic Drug Monitoring

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

1200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-09-01

Study Completion Date

2026-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, the investigators will focus on hospitalized patients using cyclosporine and develop an acute kidney injury risk prediction model through in-depth analysis of electronic medical record data, employing interpretable deep learning methods. This model aims to provide timely decision-making support for clinicians regarding prevention and treatment. Compared to traditional machine learning models, deep neural network models can extract deeper features from complex medical data and perform more precise pattern recognition, thereby improving the accuracy and reliability of predictions. By developing a prediction tool based on interpretable deep learning models, the investigators will be able to better assess the association between the use of CNI-class immunosuppressants and acute kidney injury, explore targeted prevention strategies, and offer more accurate prediction and intervention guidance for clinicians. Additionally, this study has significant socioeconomic benefits and promising prospects for application and promotion.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Deep Learning Model and Risk Factors for Tacrolimus-related Acute Kidney Injury

NCT06596798

AKI

ACTIVE_NOT_RECRUITING

Risk Factors and Machine Learning Model for Aminoglycines Related Acute Kidney Injury

NCT05533593

Aminoglycoside Toxicity Acute Kidney Injury

COMPLETED

Risk Factors and Deep Learning Model for CI-AKI

NCT06596785

AKI - Acute Kidney Injury

ACTIVE_NOT_RECRUITING

Assessment of AI Prediction Models in Prediction of Acute Kidney Injury in Critical Patients

NCT06857188

Acute Kidney Failure Artificial Intelligence (AI)

NOT_YET_RECRUITING

Achieving Medication Safety During Acute Kidney Injury

NCT01134900

Kidney Failure, Acute

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

AKI Therapeutic Drug Monitoring (TDM)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. During hospitalization, tacrolimus or cyclosporine was used, and therapeutic drug monitoring was conducted according to standard procedures.
2. Aged 18 years or older at the time of admission.
3. Length of hospital stay \> 48 hours.
4. At least 2 serum creatinine tests were conducted during hospitalization.

Exclusion Criteria

1. Chronic kidney disease stage 5 was achieved before admission.
2. Incomplete clinical data.
3. Serum creatinine levels were consistently below 40 mmol/L during hospitalization.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes